Search
Now showing items 1-1 of 1
Investigating ALK inhibitors alone or in combination as therapeutic options for ALK-positive neuroblastoma
(2021-11-16)
Neuroblastoma (NBL) is the third most common pediatric cancer after leukemia and cranial tumours and accounts for around 15% of death in pediatric malignancy. NBL develops due to the poorly differentiated progenitor cells ...